GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
2.000
-0.130 (-6.10%)
At close: Jun 5, 2026, 4:00 PM EDT
2.080
+0.080 (4.00%)
After-hours: Jun 5, 2026, 7:56 PM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,727,000
Market Cap
2.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Calidi Biotherapeutics | 29 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Adial Pharmaceuticals | 5 |
| CDT Equity | 4 |
GRI News
- 20 days ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire
- 24 days ago - GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline - GlobeNewsWire
- 25 days ago - GRI Bio Quarterly report: Q1 2026 - Filings
- 25 days ago - GRI Bio Earnings release: Q1 2026 - Filings
- 2 months ago - GRI Bio receives UAE patent allowance for inflammatory disease treatments - TheFly
- 2 months ago - GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions - GlobeNewsWire
- 3 months ago - GRI Bio Slides: Corporate presentation - Filings
- 3 months ago - GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment - GlobeNewsWire